Tourette syndrome

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
목요일, 5월 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

The American private investment fund XY Booster enhances neurodivergent talent

Retrieved on: 
화요일, 5월 7, 2024
Stanford University, Neurodiversity, Tourette syndrome, Work, Dyslexia, Workplace, Developmental coordination disorder, ADHD, Dyscalculia, Employment, Environment, Attention deficit hyperactivity disorder, Workforce, Multimedia, XY, Organization, Creative industries

NEW YORK, May 7, 2024 /PRNewswire/ -- Between 15 and 20% of the world's population is neurodivergent, according to Stanford University's Neurodiversity at Work program. This percentage reveals that at least one in every six people has conditions such as dyslexia, attention deficit hyperactivity disorder (ADHD), Tourette syndrome, dyspraxia and dyscalculia or belongs to the autism spectrum.

Key Points: 
  • XY Booster , with offices in New York, San Francisco, Mexico and Barcelona (Spain), has 40% neurodivergent talent in its workforce.
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Between 15 and 20% of the world's population is neurodivergent, according to Stanford University's Neurodiversity at Work program.
  • According to Mark Long, Chief Marketing Officer of the startup XtraordinarY, focused on enhancing neurodivergent talent and backed by the American private investment fund XY Booster , "creating an environment favorable to neurodiversity and investing in it is beneficial for everyone.
  • "By embracing neurodiversity in the team and in its investment practices, XY Booster can unlock new opportunities, improve decision-making processes, and increase its overall effectiveness as a fund.

Neupulse Secures Funding to Advance World’s First Wearable Device to Tackle Tourettes Syndrome

Retrieved on: 
월요일, 3월 18, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Biotechnology, Hardware, Health, General Health, Tic, University, Education, TS, Eos, Tourette syndrome, Quality of life, Pain, Median nerve, Multimedia, Wrist, Work, Social integration, Pharmaceutical industry

Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.

Key Points: 
  • Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.
  • Clinical trials in 2023 showed the Neupulse device can reduce tics by over 25 percentile.
  • Tourettes Syndrome is a neurological condition characterized by involuntary, repetitive movements and vocalizations known as tics.
  • Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy.

Government Employees Have Low Awareness of Neurodiversity in the Workplace, According to New Eagle Hill Consulting Research

Retrieved on: 
수요일, 3월 20, 2024
Government, Culture, Tourette syndrome, Communication, Thought, Box, Federation, Ipsos, Dyscalculia, Research, Neurodiversity, Time management, Attention deficit hyperactivity disorder, Strategy, Dyslexia, Workforce, Multimedia, Workplace, Developmental coordination disorder, Management

ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Sixty-one percent of government employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting. While 85 percent of government employees say they would hire, or have hired, a neurodivergent employee, few are trained on working with or managing neurodivergent workers. 

Key Points: 
  • ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Sixty-one percent of government employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting .
  • Jezior added, "It's encouraging to see that government employees are more cognizant of neurodiversity as compared to private sector workers.
  • In a new national poll of government employees , Eagle Hill found:
    Sixty percent of government employees say training in sensitivity to social differences would be valuable, and 62 percent indicated they would be interested in training on managing neurodivergent employees.
  • These findings are from the Eagle Hill Consulting Neurodiversity in Government Survey conducted by Ipsos from January 11-18, 2024.

New Eagle Hill Consulting Research Finds U.S. Employees Have Low Awareness of Neurodiversity in the Workplace

Retrieved on: 
월요일, 3월 18, 2024
Culture, Organization, Tourette syndrome, Ipsos, Dyscalculia, Research, News, Neurodiversity, Time management, Condition, Attention deficit hyperactivity disorder, Strategy, Dyslexia, Workplace, Potential, Multimedia, Developmental coordination disorder, Management

ARLINGTON, Va., March 18, 2024 /PRNewswire/ -- Sixty-eight percent of U.S. employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting. While 72 percent of employees say they would hire a neurodivergent employee, few workers are trained on working with or managing neurodivergent workers. 

Key Points: 
  • These findings are detailed in a new report, Neurodiversity in the Workplace : Are Organizations Overlooking Their Highly Capable Neurodivergent Employees When Creating the Conditions for Corporate Success?
  • The new Eagle Hill research finds that when evaluating employee performance, most consider the ability to communicate clearly (55 percent) and stay organized (54 percent), as important evaluation criteria, skills that often are challenging for neurodivergent employees.
  • These findings are from the Eagle Hill Consulting Neurodiversity in the Workplace Survey conducted by Ipsos from January 11-18, 2024.
  • Eagle Hill Consulting LLC is a woman-owned business that provides unconventional management consulting services in the areas of Strategy & Performance, Talent, and Change.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
목요일, 2월 15, 2024
MorphoSys, Pfizer, European Commission, Recurrence, Docetaxel, Roche, Cystic fibrosis, Share repurchase, FDA, Food, Schizophrenia, Growth, Sacituzumab govitecan, PTC, Vertex, Astellas Pharma, Risdiplam, Metastasis, Projection, KarXT, Bristol Myers Squibb, PTC Therapeutics, Endocrine gland, Lung cancer, Civil service commission, JAK, Therapy, Tourette syndrome, Webcast, Patient, Cytokinetics, Eastern Time Zone, Novartis, Ruxolitinib, NDA, Pharmaceutical industry

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

Retrieved on: 
금요일, 11월 10, 2023
Ministry, Safety, TS, Food, Yale University, Disorder, THC, Clinical trial, Medical device, Patient, IIA, FDA, Movement, Hannover Medical School, Cannabinoid, Tourette syndrome, Learning, Central nervous system, Tic, TEL, PEA, Pharmaceutical industry, Dronabinol, Health

TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced the initiation of its Phase IIb clinical trial treating patients suffering from Tourette Syndrome (TS) with its SCI-110, proprietary drug candidate.

Key Points: 
  • SciSparc initiated the trial at the Tel Aviv Sourasky Medical Center in Israel (Sourasky) and is expected to proceed with its U.S. and Germany-based medical sites.
  • TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.
  • In addition, the medication was generally well-tolerated by subjects and 12 out of the 16 subjects elected to continue into a 24-week extension phase of the trial.

Tech Industry Making Progress Building Diverse Teams and Prioritizing Personalized Career Progression, According to hackajob's Latest Industry Report

Retrieved on: 
수요일, 11월 29, 2023
Woman, Senior, Organization, Dyslexia, ADHD, Tourette syndrome, Autism spectrum, AI, Workplace, Outline, Environment, Gartner, Architecture, Management, Creative industries

NEW YORK, Nov. 29, 2023 /PRNewswire-PRWeb/ -- hackajob, the full stack technical hiring platform, today released its industry report: "Unveiling Emerging Tech Talent Trends in 2024 and Beyond." The results outline several tech talent recruiting and career development themes. Amongst emerging trends, a highlight is the increased importance organizations are placing on diversity, equity, and inclusion as they build their tech teams and foster ongoing career progression.

Key Points: 
  • NEW YORK, Nov. 29, 2023 /PRNewswire-PRWeb/ -- hackajob , the full stack technical hiring platform, today released its industry report: "Unveiling Emerging Tech Talent Trends in 2024 and Beyond."
  • The results outline several tech talent recruiting and career development themes.
  • Amongst emerging trends, a highlight is the increased importance organizations are placing on diversity, equity, and inclusion as they build their tech teams and foster ongoing career progression.
  • In 2023, the demand for tech talent remained high despite the economy.

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

Retrieved on: 
목요일, 10월 5, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Paragon, Weight gain, Disease, Antipsychotic, Tic, Anxiety, Pediatrics, Mortality, Safety, Vital signs, Somnolence, Effectiveness, Insomnia, International Congress on Tuberculosis, Tourette syndrome, Ars, Patient, Pharmaceutical industry, MD

An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.

Key Points: 
  • An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.
  • No new safety concerns were identified based on an evaluation of adverse events, physical exams, vital signs, laboratory results and safety scales, according to Emalex Biosciences.
  • Ecopipam is the lead candidate for Emalex Biosciences, a clinical-stage biopharmaceutical company founded by Paragon Biosciences.
  • The 12-month data supports the continued development of ecopipam as a first-in-class novel therapy for children and adolescents with Tourette syndrome,” said Emalex Biosciences Chief Medical Officer Frederick Munschauer, MD.

Morocco Medical Cannabis Market Size, Share & Trends Analysis Report 2023: Market to Reach $537.7 Million by 2030, Growing at a CAGR of 48% with Bio Cannat & PharmaCielo Dominating - ResearchAndMarkets.com

Retrieved on: 
금요일, 9월 15, 2023
Alternative Medicine, Health, Tourette syndrome, Syndrome, Education, Flower, Research, USD, Pain, Depression, Incidence, Patient, Oil, Chronic pain, Growth, Drug, Pharmaceutical industry, Anxiety, Cancer

The global demand for medical cannabis continues to rise, driven by growing recognition of its therapeutic potential.

Key Points: 
  • The global demand for medical cannabis continues to rise, driven by growing recognition of its therapeutic potential.
  • The Moroccan government's proactive steps to legalize and regulate the cannabis sector respond to the global demand for legal marijuana, particularly medical cannabis.
  • Morocco's historical role as one of the world's largest marijuana producers in the northern region positions it favorably in the market.
  • Now, with formalization, Morocco aims to harness the economic benefits of the sector and meet the demand for legal marijuana.